Silverfleet Capital sells Sterigenics to GTCR for $675 million
London-based buyout firm Silverfleet Capital said Wednesday it is selling Illinois-based medical services company Sterigenics International to GTCR, a US private equity firm for $675 million.
Provectus Pharmaceuticals, a biotech company developing oncology and dermatology drugs, has inked a $1 million investment from Chicago-based Lincoln Park Capital Fund.